Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients

Antibody-mediated rejection (AMR) continues to have a deleterious impact on kidney allograft survival. Recent evidence supports use of tocilizumab for treatment of chronic active AMR, but it has not been assessed for treatment of acute active AMR. METHODS. We performed a single-center, observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Pottebaum, April A., Venkatachalam, Karthikeyan, Liu, Chang, Brennan, Daniel C., Murad, Haris, Malone, Andrew F., Alhamad, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145000/
https://www.ncbi.nlm.nih.gov/pubmed/32309629
http://dx.doi.org/10.1097/TXD.0000000000000988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145000/
https://www.ncbi.nlm.nih.gov/pubmed/32309629
http://dx.doi.org/10.1097/TXD.0000000000000988

Ejemplares similares